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Abstract: Chemically durable microspheres containing yttrium and/or phosphorus are 
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useful for intra-arterial radiotherapy. In the present study, we attempted to prepare 
yttrium phosphate (YPO4) microspheres with high chemical durability. YPO4 
microspheres with smooth surfaces and diameters of around 25 µm were successfully 
obtained when gelatin droplets containing yttrium and phosphate ions were cooled 
and solidified in a water-in-oil emulsion and then heat-treated at 1100ºC. The 
chemical durability of the heat-treated microspheres in a simulated body fluid at pH = 
6 and 7 was high enough for clinical application of intra-arterial radiotherapy. 
Keywords: yttrium phosphate; chemical durability; microspheres; intra-arterial 
radiotherapy 
INTRODUCTION 
Intra-arterial radiotherapy of malignant liver tumors has been performed using radioactive 
yttrium-containing microspheres.1,2 Yttrium-89 (89Y) is a nonradioactive isotope with a natural
abundance of 100%; neutron bombardment activates 89Y to form the β-emitter 90Y,
which has a half-life of 64.1 h. When radioactive microspheres 20–35 µm in diameter are 
injected into a target organ, they are trapped inside small blood vessels in the tumor, blocking 
the nutritional supply to the tumor and delivering a large, localized dose of short-range, highly 
ionizing β-rays. The β-rays penetrate only about 2.5 mm in living tissue, thus causing little 
radiation damage to neighboring healthy tissues. These microspheres show high chemical 
durability, and the radioactive 90Y remains essentially within the microspheres and does not 
affect neighboring healthy tissues. The radioactivity of 90Y decays to a negligible level within
21 days after neutron bombardment. The microspheres therefore become inactive soon after 
the cancer treatment. 
So far, Y2O3–Al2O3–SiO2 (YAS) glass microspheres (TheraSphere)3-5 and 
yttrium-containing resin microspheres (SIR-Spheres)6-8 have yielded good results in clinical 
trials.9–12 They have been used clinically to treat unresectable hepatocellular carcinoma in
various countries including the USA, Canada, China, Australia, New Zealand and 
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Singapore.13–28 The Y2O3 content in TheraSpheres is 17 mol%, and the yttrium content in
SIR-Spheres is around 2 mol%. The radioactivity of these microspheres decays significantly 
even before cancer treatment is started because of the short half-life. Therefore, the 
development of chemically durable microspheres having a higher yttrium content is desirable. 
We have developed dense Y2O3 microspheres,29 hollow Y2O3 microspheres,30 and porous
Y2O3 microparticles31 with high chemical durability in vitro.
On the other hand, phosphorus-31 (31P), found at a natural abundance of 100%, can also
be activated by neutron bombardment to form the β-emitter 32P, which has a half-life of 14.3
days. Microspheres containing a high phosphorus content are therefore expected to be 
effective for cancer treatment, similar to yttrium-containing microspheres.32,33 Previously, we
attempted to prepare yttrium phosphate (YPO4) microspheres by a high-frequency induction 
thermal plasma melting method and found that they showed high chemical durability in
vitro.29 However, they lost a certain amount of phosphorus to form Y2O3, and their surfaces
were rather rough owing to the loss of phosphorus from volatilization at the higher synthesis 
temperatures (above 10,000ºC). It is feared that the rough surfaces of the microspheres would 
damage blood vessels. In this study, we attempted to prepare YPO4 microparticles with a 
smooth surface and investigated their structure and in vitro chemical durability in order to 
evaluate their potential as a radioactive source in intra-arterial radiotherapy. 
MATERIALS AND METHODS 
Sample preparation 
A precursor precipitate containing yttrium and phosphate ions was obtained by the following 
solution precipitation process.34 Equimolar (8.4 mM) amounts of yttrium nitrate (Y[NO3]3:
Wako Pure Chemical Industries Ltd., Osaka, Japan) and phosphoric acid (H3PO4: Wako Pure 
Chemical Industries Ltd., Osaka, Japan) were dissolved in 300 mL of pure water. Aqueous 
NaOH solution (56 mM, 150 mL) was added to the Y(NO3)3–H3PO4 solution under stirring 
for 20 min, resulting in an opaque solution. This opaque solution was centrifuged at 4000 rpm 
for 5 min and decanted to obtain white precipitates. The precipitates were washed several 
times with pure water. Then, 2.5 mL of 0.1M nitric acid aqueous solution was added to 10 g 
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4 
of the white precipitates to obtain a stable sol solution.35 Gelatin (0.5 g; APH-250, Nitta
Gelatin Inc., Osaka, Japan) was dissolved in 5 mL of the sol solution. The resultant solution 
was dropped into 50 mL of corn oil (Wako Pure Chemical Industries Ltd., Osaka, Japan) at 
30ºC and stirred at 1000 rpm for 10 min to obtain a water-in-oil emulsion. The emulsion was 
cooled in an ice bath to solidify the gelatin-containing water droplets. The solidified droplets 
were filtered and washed with cold ethanol and then freeze-dried for 6 h in a freeze dryer 
(FD-1000; Tokyo Rikakikai Co. Ltd., Tokyo, Japan). Finally, the freeze-dried samples were 
placed in an alumina boat, heated to various temperatures (700−1500°C) at a rate of 
5°C·min–1 in a SiC or MoSi2 electric furnace, and kept at the given temperature for 1 h.
Structural analysis 
The shapes of the microspheres were observed using a scanning electron microscope (SEM; 
VE-8800, Keyence, Tokyo, Japan). The precipitated phase was examined with a powder 
X-ray diffractometer (XRD; RINT-2200VL, Rigaku Co. Ltd., Tokyo, Japan) using the
following settings: X-ray source, Ni-filtered CuKα radiation; X-ray power, 40 kV, 40 mA; 
scanning rate, 2θ = 2°·min–1; and sampling angle, 0.02°. The structure of the heat-treated
microspheres before and after an in vitro chemical durability test was investigated by 
Fourier-transform infrared spectroscopy (FT-IR; FT/IR-6200, JASCO, Tokyo, Japan) with a 
diffusive reflection attachment (DR-PRO410M, JASCO, Tokyo, Japan). For the FT-IR 
diffusive reflection spectroscopic measurement, potassium bromide (KBr) powder was mixed 
with the samples. The sample content in KBr pellets was around 0.5 wt%. 
In vitro chemical durability test 
A simulated body fluid (SBF) with ion concentrations of Na+ 142.0, K+ 5.0, Mg2+ 1.5, Ca2+
2.5, Cl− 147.8, HCO3− 4.2, HPO42− 1.0, and SO42− 0.5 mM was prepared by dissolving
reagent-grade NaCl, NaHCO3, KCl, K2HPO4·3H2O, MgCl2·6H2O, CaCl2, and Na2SO4 (Nacali 
Tesque Inc., Kyoto, Japan) in ultrapure water and buffering to pH 7.40 with 
tris(hydroxymethyl) aminomethane ([CH2OH]3CNH2) and 1M HCl (Nacali Tesque Inc., 
Kyoto, Japan) at 36.5ºC.36 Then, the pH value of the SBF was adjusted to 6 (SBF-6) or 7
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5 
(SBF-7) by further addition of 1M HCl. 
The microspheres (0.025 g) heat-treated at 1100ºC were soaked in 10 mL of SBF-6 or 
SBF-7 in a polypropylene bottle at 36.5ºC for various periods up to 21 days. The pH value of 
a normal body fluid is maintained at around pH 7, but this value is liable to fall to around pH 
6 near a cancer owing to the production of lactic acid.37 The SBF was shaken at a rate of 120
strokes·min–1 using a stroke length of 3 cm. The samples were soaked for up to 21 days, since
the radioactivity of 90Y decays to a negligible level after 21 days. An inductively coupled
plasma (ICP) atomic emission spectrometer (Optima 2000DV, PerkinElmer Co., Ltd., 
Germany) was used to determine the concentrations of yttrium and phosphorus released from 
the microspheres into SBF-6 or SBF-7. The fraction of yttrium released from the 
microspheres was calculated using the following formula. 
(mol) emicrospher in the contained yttrium ofquantity molar  Total
(mol) SBF  theinto emicrospher  thefrom released yttrium ofquantity Molar fraction Released =
RESULTS 
Figure 1 shows XRD patterns of samples before and after heat treatment at different 
temperatures. The untreated sample exhibited a halo, indicating that its structure was 
amorphous. Several peaks of tetragonal YPO4 with the xenotime structure (PDF File No. 
11-0254) were clearly observed after heat treatment at temperatures above 700ºC. With a
further increase in heat treatment temperature to 1500ºC, the structure of the sample remained 
dehydrated YPO4 with tetragonal xenotime-type structure,34 but the diffraction peaks became
more intense and narrower, indicating crystal growth of YPO4 with increasing heat treatment 
temperature. 
Figure 2 shows SEM photographs of samples before and after heat treatment at different 
temperatures. Microspheres around 25 µm in diameter with smooth surfaces were 
successfully obtained by the present method, although their diameters ranged from 10 to 80 
µm. The surface smoothness of the microspheres was improved slightly by heat treatment at 
700ºC or 1100ºC. This might be attributed to partial sintering of YPO4 by the heat treatment. 
With heat treatment at 1500ºC, the surface of the microspheres became rather rough, and 
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remarkable aggregation of the microspheres occurred. It seems plausible that the 
microspheres heat-treated at higher temperatures will show higher chemical durability in the 
human body, since sintering of YPO4 will proceed at higher temperatures. However, the rough 
surface and aggregation of the microspheres are unfavorable for clinical application of 
intra-arterial therapy. Therefore, we considered that the maximum useful heat treatment 
temperature is 1100ºC, and an in vitro chemical durability test was conducted for the 
microspheres heat-treated at 1100ºC in this study. Figure 3 shows SEM photographs of 
cross-sections of these microspheres. Figures 2 and 3 show that both the inside and the outer 
surface of the microspheres heat-treated at 1100ºC were dense. 
Figure 4 shows the concentrations of yttrium and phosphorus released from the 
microspheres heat-treated at 1100ºC into SBF-6 or SBF-7 after immersion for 21 days, in 
comparison with those of the original SBF without soaking of the microspheres. The 
concentrations of yttrium released from the microspheres into SBF-6 and SBF-7 were as low 
as 0.3 mg/g, which is almost the same as the yttrium concentration of the original SBF 
without microsphere soaking (Fig. 4[a]). It is interesting to note that the concentrations of 
phosphorus in SBF-6 and SBF-7 in which the microspheres were soaked for 21 days were 
slightly lower than those of the original SBF (Fig. 4[b]). This suggests that the microspheres 
heat-treated at 1100ºC released hardly any yttrium into either SBF-6 and SBF-7 after 21 days, 
and a small amount of phosphorus might adsorb onto the surfaces of the microspheres. 
Figure 5 shows the XRD patterns (a) and SEM photographs (b) of the microspheres 
heat-treated at 1100ºC before and after soaking in SBF-6 and SBF-7 for 21 days. No 
appreciable change was observed in the XRD patterns and the SEM photographs of the 
microspheres after soaking in either of the SBF solutions. Figure 6 shows the FT-IR diffusive 
spectra of the microspheres heat-treated at 1100ºC before and after soaking in SBF-6 and 
SBF-7 for 21 days. The microspheres before soaking showed several bands assigned to 
PO4.38,39 The bands at around 3500 cm–1 and 1630 cm–1, which are assigned to H2O,38,39
appeared after the microspheres were soaked in SBF-6 or SBF-7. This might be attributed to 
partial hydration of the microspheres’ surfaces due to the chemical durability test. The 
intensity of the bands at around 1300 and 3000 cm–1 increased after the chemical durability
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7 
test. These two bands are assigned to PO4 and CH3, respectively.38-40 This result suggests
adsorption of a small amount of phosphorus-containing organic compounds onto the surfaces 
of the microspheres, although the detailed structure of the compounds is unclear. Also, it is 
consistent with the results of the in vitro chemical durability test, indicating that the 
concentrations of phosphorus in SBF-6 and SBF-7 in which the microspheres were soaked for 
21 days were slightly lower than those of the original SBF (see Fig. 4). According to these 
results, we can conclude that the present microspheres heat-treated at 1100ºC are quite 
chemically stable under acidic and neutral SBF solutions. 
DISCUSSION 
We examined the durability of the heat-treated microspheres by immersion for 21 days in 
SBF (Fig. 4). Note, however, that the radioactivity of 32P decays to a negligible level only
after 112 days, and hence it might be advisable to evaluate the chemical durability of the 
microspheres for a longer period of 112 days. However, we can expect that the present YPO4 
microspheres would show high chemical durability for long periods such as 112 days because 
we confirmed that microspheres consisting of YPO4 and Y2O3 (YPO4–Y2O3 microspheres) 
showed excellent chemical durability for 112 days in saline with both pH = 6 and pH = 7 in 
our previous study.29 Moreover, the activity product of YPO4 is reportedly as low as 10–24.76 at
25±1ºC.41
In Table 1, the fraction of yttrium released from the present YPO4 microparticles is 
compared with that of previously reported samples. The present YPO4 microspheres showed 
smaller released yttrium fractions than the previously reported samples, although the chemical 
durability of some samples (dense Y2O3 microspheres, YPO4–Y2O3 microspheres, and 
Y2O3–Al2O3–SiO2 [TheraSphere-type] glass) was evaluated in saline solutions buffered at
pH = 6 or 7. In particular, we noted that the fraction of yttrium released from the present 
YPO4 microspheres was much smaller than that from TheraSphere-type glass and dense
Y2O3 microspheres, which showed no acute toxicity in animal tests,42 indicating that the
chemical durability of the present YPO4 microspheres is high enough for clinical application 
in intra-arterial radiotherapy. 
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8 
CONCLUSIONS 
YPO4 microspheres around 25 µm in diameter with smooth surfaces were successfully 
obtained by cooling and solidifying gelatin droplets containing yttrium phosphate precursor 
precipitates in a water-in-oil emulsion and then heat-treating them at 1100ºC. The in vitro 
chemical durability of the heat-treated microspheres in a simulated body fluid at pH = 6 and 7 
was high enough for clinical application of intra-arterial radiotherapy. We believe that the 
present YPO4 microspheres are useful for intra-arterial radiotherapy of cancer, since they have 
smooth surfaces and can be activated to β-emitters by neutron bombardment. 
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Table legends and figure captions 
Table 1 Fraction of yttrium released from the samples into SBF-6, SBF-7, and saline 
solutions buffered at pH = 6 or 7 at 36.5ºC for 21 days. 
Figure 1 XRD patterns of samples before and after heat treatment at different temperatures. 
Figure 2 SEM photographs of samples before and after heat treatment at different 
temperatures. 
Figure 3 SEM photographs of cross-sections of samples after heat treatment at 1100ºC. 
Figure 4 Concentrations of yttrium and phosphorus released from the microspheres 
heat-treated at 1100ºC into SBF-6 or SBF-7 after 21 days, in comparison with 
those of the original SBF without soaking of the microspheres. 
Figure 5 XRD patterns (a) and SEM photographs (b) of the microspheres heat-treated at 
1100ºC before and after soaking in SBF-6 or SBF-7 for 21 days. 
Figure 6 FT-IR diffusive spectra of samples before and after soaking in SBF-6 or SBF-7 for 
21 days. 
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Table 1 Fraction of yttrium released from the samples into SBF-6, SBF-7, and saline solutions buffered at pH = 6 or 7 at 36.5ºC for 21 days. 
Immersion fluid 
Sample 
SBF-6 SBF-7 
Present YPO4 microspheres 2.5 × 10-5 2.5 × 10-5
Hollow Y2O3 microspheres30) 1.8 × 10-3 1.3 × 10-3
Porous Y2O3 microparticles31) 5.6 × 10-3 5.2 × 10-3
Saline solutions buffered at pH = 6 Saline solutions buffered at pH = 7 
Dense Y2O3 microspheres29) 4 × 10-3 2 × 10-3
YPO4-Y2O3 microspheres29) 2.5 × 10-3 undetectable level 
Y2O3-Al2O3-SiO2 (TheraSphere-type) glass29) 9 × 10-3 3 × 10-3
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